MaxCyte Inc (MXCT)
London Exchange · UK · prices in GBX · close of 15 Oct 2026
Key indicators
| Last close | GBX 1.300 |
|---|---|
| 52-week range | 0.643 – 1.865 |
| Return, 1 month / 3 months | +9.2% / −8.5% |
| Return, 1 year / 3 years | −29.0% / −55.3% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 70.2% |
| Worst drawdown (1 year) | -63.0% |
| Average daily value traded | 1.02M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MaxCyte is a cell-engineering company that supplies instruments and related services used to modify cells for research and therapeutic development. Its technology helps biopharmaceutical firms and academic laboratories introduce genetic material into cells, supporting work on cell therapies and biologic medicines. The company is based in Gaithersburg, Maryland, in the United States, and its customers include drug developers and research institutions around the world.
MaxCyte Inc trades under the code MXCT on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MaxCyte Inc (MXCT) trades on the London Exchange in UK. It last closed at GBX 1.300 on 15 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 2,385 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 29.0% and over the last three months it fell 8.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 22.5% | ||
| From 52-week high | -29.0% | ||
| Momentum | 46 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.5% | ||
| 6-month return | 53.8% | ||
| 12-month return, skipping the last month | -35.0% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 70.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -63.0% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.02M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +27.5% |
|---|---|
| 1 month | +9.2% |
| 3 months | −8.5% |
| 6 months | +53.8% |
| 1 year | −29.0% |
| 3 years | −55.3% |
| 5 years | −88.2% |
Signals
| 50-day / 200-day average | 1.210 / 1.061 |
|---|---|
| Golden / death cross (60 days) | Golden, 58 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.078 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.